155 related articles for article (PubMed ID: 38169532)
21. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
22. Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.
Zeng X; Zhao F; Jia J; Ma X; Jiang Q; Zhang R; Li C; Wang T; Liu W; Hao Y; Tao K; Lou Z; Zhang P
Cancer Res; 2023 Nov; 83(21):3624-3635. PubMed ID: 37556508
[TBL] [Abstract][Full Text] [Related]
23. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
[TBL] [Abstract][Full Text] [Related]
24. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
25. BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
Li K; Liu Y; Ding Y; Zhang Z; Feng J; Hu J; Chen J; Lian Z; Chen Y; Hu K; Chen Z; Cai Z; Liu M; Pang X
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377663
[TBL] [Abstract][Full Text] [Related]
26. BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress.
Fernando TM; Marullo R; Pera Gresely B; Phillip JM; Yang SN; Lundell-Smith G; Torregroza I; Ahn H; Evans T; Győrffy B; Privé GG; Hirano M; Melnick AM; Cerchietti L
Cancer Discov; 2019 May; 9(5):662-679. PubMed ID: 30777872
[TBL] [Abstract][Full Text] [Related]
27. BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
Guo J; Liu Y; Lv J; Zou B; Chen Z; Li K; Feng J; Cai Z; Wei L; Liu M; Pang X
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33393503
[TBL] [Abstract][Full Text] [Related]
28. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
30. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
31. The feedback loop of LITAF and BCL6 is involved in regulating apoptosis in B cell non-Hodgkin's-lymphoma.
Shi Y; Kuai Y; Lei L; Weng Y; Berberich-Siebelt F; Zhang X; Wang J; Zhou Y; Jiang X; Ren G; Pan H; Mao Z; Zhou R
Oncotarget; 2016 Nov; 7(47):77444-77456. PubMed ID: 27764808
[TBL] [Abstract][Full Text] [Related]
32. miR-144-3p inhibits cell proliferation of colorectal cancer cells by targeting BCL6 via inhibition of Wnt/β-catenin signaling.
Sun N; Zhang L; Zhang C; Yuan Y
Cell Mol Biol Lett; 2020; 25():19. PubMed ID: 32206063
[TBL] [Abstract][Full Text] [Related]
33. B-cell lymphoma 6 promotes proliferation and survival of trophoblastic cells.
Muschol-Steinmetz C; Jasmer B; Kreis NN; Steinhäuser K; Ritter A; Rolle U; Yuan J; Louwen F
Cell Cycle; 2016; 15(6):827-39. PubMed ID: 27029530
[TBL] [Abstract][Full Text] [Related]
34. Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway.
Islam SS; Aboussekhra A
J Exp Clin Cancer Res; 2019 Aug; 38(1):382. PubMed ID: 31470883
[TBL] [Abstract][Full Text] [Related]
35. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
36. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.
Ranuncolo SM; Polo JM; Melnick A
Blood Cells Mol Dis; 2008; 41(1):95-9. PubMed ID: 18346918
[TBL] [Abstract][Full Text] [Related]
37. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
38. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer.
Dai Y; Jin S; Li X; Wang D
Oncotarget; 2017 Jan; 8(1):1354-1368. PubMed ID: 27935869
[TBL] [Abstract][Full Text] [Related]
39. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
40. Ikaros regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia.
Ge Z; Zhou X; Gu Y; Han Q; Li J; Chen B; Ge Q; Dovat E; Payne JL; Sun T; Song C; Dovat S
Oncotarget; 2017 Jan; 8(5):8022-8034. PubMed ID: 28030830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
